| 1 |
35418303 | Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERĪ± expression and proliferation in luminal primary and metastatic breast cancer cells. | 2022 Apr 13 |
1 |
| 2 |
35430566 | SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy. | 2022 May-Jun |
1 |
| 3 |
34081985 | Checkpoint kinases are required for oocyte meiotic progression by the maintenance of normal spindle structure and chromosome condensation. | 2021 Aug 15 |
1 |
| 4 |
32857208 | Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin. | 2020 Nov |
2 |
| 5 |
30633885 | Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762. | 2019 Feb 15 |
1 |
| 6 |
24362713 | Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. | 2014 Jan |
1 |
| 7 |
23892959 | Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. | 2013 Sep |
1 |
| 8 |
22189968 | Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762. | 2012 Feb 15 |
3 |